Abera Bioscience Wins Dutch Approval for Phase 1 Pneumococcal Vaccine Trial

PUBT · 1d ago
Abera Bioscience Wins Dutch Approval for Phase 1 Pneumococcal Vaccine Trial
  • Abera Bioscience received Dutch regulator CCMO's clearance to begin a Phase 1 trial of its nasal pneumococcal vaccine candidate Ab-01.12.
  • The first-in-human study at Radboud UMC will assess safety and tolerability in up to 25 healthy adults aged 18–49.
  • Recruitment remains subject to local authorization at Radboud UMC.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abera Bioscience AB published the original content used to generate this news brief via Cision (Ref. ID: 202611040252BITN____UKPR__SV_20261104-BIT-4526-0) on November 04, 2026, and is solely responsible for the information contained therein.